Homologous News and Research

RSS

Newcastle disease virus-based trivalent vaccine found to be effective across SARS-CoV-2 variants in mice

In a new study, researchers tested the bi-, tri-, and tetravalent formulations of Newcastle disease virus (NDV)-based low-cost vaccine in mice.

29 Mar 2022

Benefits of heterotypic vaccination against variants of SARS-CoV-2

A new study evaluated the antibody responses against the newly emerged SARS-CoV-2 Omicron variant upon heterotypic vaccination in animal models.

28 Mar 2022

Mathematical model of SARS-CoV-2 transmission tailored to the unique situation of China

Researchers designed a dynamic mathematical model to simulate the transmission of the SARS-CoV-2 Omicron variant in China and project its associated burden on healthcare facilities, should the zero-COVID-19 policy be lifted.

28 Mar 2022

Study investigates anti-SARS-CoV-2 antibody levels following Pfizer vaccine primary and booster regimens

A new study presented the differences among total anti-SARS-CoV-2 antibodies following SARS-CoV-2 Pfizer primary and booster vaccinations.

24 Mar 2022

UB-612 vaccine booster found to elicit high neutralizing antibody levels against SARS-CoV-2 Omicron

Researchers evaluated the effectiveness of a novel vaccine candidate UB-612 against 14 SARS-CoV-2 variants, including the latest variant of concern, Omicron.

24 Mar 2022

Waning antibody responses in SARS-CoV-2-infected or vaccinated population

A recent study posted to the bioRxiv* preprint server evaluated the effects of the waning of antibodies after coronavirus disease 2019 (COVID-19) infection or vaccination.

22 Mar 2022

Research characterizes efficacy of various COVID vaccines against Omicron BA.1 and BA.2

A recent study posted to the bioRxiv* preprint server demonstrated the neutralizing capacity of existing SARS-CoV-2 vaccines against the severe acute respiratory coronavirus 2 (SARS-CoV-2) Omicron BA.2 and BA.1 sublineages.

22 Mar 2022

HRR mutational status associated with survival outcomes in recurrent platinum-sensitive ovarian cancer

Results of a biomarker analysis of the NRG Oncology NRG-GY004 trial were presented at a Seminal Session during the Society for Gynecologic Oncology's (SGO) Annual Meeting on Women's Cancer in March 2022.

19 Mar 2022

BNT162b2 booster vaccination induces robust humoral and cellular immune responses

Scientists evaluate the humoral and cellular immune responses in individuals who have received a third booster dose of mRNA-based COVID-19 vaccine.

17 Mar 2022

The immunogenicity of homologous and heterologous boosters in adults who received inactivated COVID-19 vaccine six months prior

Researchers compared the efficacy of booster doses of heterologous intramuscular and aerosolized adenovirus-vectored vaccine, a recombinant protein-based ZF2001 vaccine, and homologous CoronaVac vaccines.

17 Mar 2022

The safety and immunogenicity of NVSI-06-08 as a heterologous booster dose in adults previously vaccinated with BBIBP-CorV

Researchers assessed the safety profile and immunogenicity of a heterologous NVSI-06-08 boost against SARS-CoV-2 variants in individuals doubly vaccinated with the inactivated vaccine BBIBP-CorV.

17 Mar 2022

Vaccine effectiveness against COVID-19 severity in the elderly

Researchers assessed vaccine effectiveness against SARS-CoV-2 infection in elderly patients before and after the spread of the SARS-CoV-2 Omicron variant of concern.

17 Mar 2022

Study models SARS-CoV-2 M protein monomer and dimer 3D structures

Researchers presented new structural insights about the SARS-CoV-2 membrane protein.

15 Mar 2022

Factors influencing cross-protective serological immunity against SARS-CoV-2 variants in Asians

Researchers assessed the impact of demographic variability on the Pfizer/BioNTech BNT162b2 vaccine-induced serological immunity against SARS-CoV-2 variants of concern and variants of interest.

14 Mar 2022

Bioactive small molecules enhance CRISPR/Cas9 loss-of-function editing in human cells

Researchers demonstrate enhanced loss-of-function editing of CRISPR/Cas9 in human cells.

14 Mar 2022

Updated results from ongoing study on the effect of a BNT162b2 booster dose on anti-SARS-CoV-2 antibodies

Researchers assessed the increase in Pfizer/BioNTech BNT162b2 vaccine efficacy on administering a homologous booster dose.

11 Mar 2022

Neutralizing antibody levels before symptomatic breakthrough infection in groups infected before and after Omicron emergence

Researchers assessed the levels of neutralizing antibodies in coronavirus disease patients.

9 Mar 2022

Current progress in SARS-CoV-2 vaccine candidates

In a new study, researchers illustrated the current progress and obstacles in COVID-19 vaccine development.

7 Mar 2022

How effective is mRNA vaccination in multiple myeloma patients?

In a new study, researchers have been investigating the protection offered by the SARS-CoV-2 vaccine in patients suffering from multiple myeloma.

2 Mar 2022

Serological test to assess presence of immunoglobulin isotypes targeted against antigens routinely used in COVID-19 diagnosis

The current study discusses a reliable ELISA that can detect three isotypes of antibody against three SARS-CoV-2 antigens.

2 Mar 2022

Homologous News and Research

Newcastle disease virus-based trivalent vaccine found to be effective across SARS-CoV-2 variants in mice

Benefits of heterotypic vaccination against variants of SARS-CoV-2

Mathematical model of SARS-CoV-2 transmission tailored to the unique situation of China

Study investigates anti-SARS-CoV-2 antibody levels following Pfizer vaccine primary and booster regimens

UB-612 vaccine booster found to elicit high neutralizing antibody levels against SARS-CoV-2 Omicron

Waning antibody responses in SARS-CoV-2-infected or vaccinated population

Research characterizes efficacy of various COVID vaccines against Omicron BA.1 and BA.2

HRR mutational status associated with survival outcomes in recurrent platinum-sensitive ovarian cancer

BNT162b2 booster vaccination induces robust humoral and cellular immune responses

The immunogenicity of homologous and heterologous boosters in adults who received inactivated COVID-19 vaccine six months prior

The safety and immunogenicity of NVSI-06-08 as a heterologous booster dose in adults previously vaccinated with BBIBP-CorV

Vaccine effectiveness against COVID-19 severity in the elderly

Study models SARS-CoV-2 M protein monomer and dimer 3D structures

Factors influencing cross-protective serological immunity against SARS-CoV-2 variants in Asians

Bioactive small molecules enhance CRISPR/Cas9 loss-of-function editing in human cells

Updated results from ongoing study on the effect of a BNT162b2 booster dose on anti-SARS-CoV-2 antibodies

Neutralizing antibody levels before symptomatic breakthrough infection in groups infected before and after Omicron emergence

Current progress in SARS-CoV-2 vaccine candidates

How effective is mRNA vaccination in multiple myeloma patients?

Serological test to assess presence of immunoglobulin isotypes targeted against antigens routinely used in COVID-19 diagnosis

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News